Mechanism of action
Oxytocin is a nonapeptide hormone synthesized in the hypothalamus and stored in the posterior pituitary. The synthetic form is structurally identical to endogenous oxytocin.
Oxytocin binds to oxytocin receptors on uterine myometrial cells. These are Gq protein-coupled receptors that activate phospholipase C, leading to increased intracellular calcium concentration. The rise in calcium triggers actin-myosin interaction and uterine smooth muscle contraction.
The sensitivity of the uterus to oxytocin increases dramatically during pregnancy, particularly in the third trimester, due to upregulation of oxytocin receptors. This explains why oxytocin is more effective for labor induction at term than earlier in pregnancy.
Oxytocin also stimulates the release of prostaglandins from the decidua, which further enhance uterine contractility. Additionally, oxytocin causes contraction of myoepithelial cells in the breast, promoting milk ejection during lactation.
At high doses, oxytocin has antidiuretic effects due to structural similarity to vasopressin (ADH) and weak binding to V2 vasopressin receptors in the kidney. This can lead to water retention and hyponatremia.
- Oxytocin binds Gq-coupled receptors on myometrium, increasing intracellular calcium and causing uterine contractions.
- Uterine sensitivity to oxytocin increases dramatically in the third trimester due to receptor upregulation.
- Oxytocin is first-line for labor induction, augmentation, and postpartum hemorrhage prevention/treatment.
- Uterine tachysystole (>5 contractions/10 min) and fetal distress are the most common serious adverse effects.
- Water intoxication and hyponatremia can occur with prolonged high-dose infusion due to weak V2 receptor agonism.
- Oxytocin is contraindicated in cephalopelvic disproportion, fetal distress, and prior classical cesarean section.
- Never give oxytocin as a rapid IV bolus; it causes severe hypotension and reflex tachycardia.
- Prolonged oxytocin use can desensitize receptors, paradoxically causing postpartum uterine atony.
Indications
Obstetric indications:
- Induction of labor at or near term when continuation of pregnancy poses risks to mother or fetus (post-dates pregnancy, prelabor rupture of membranes, preeclampsia, diabetes, fetal growth restriction)
- Augmentation of labor when uterine contractions are inadequate to achieve normal progress
- Prevention of postpartum hemorrhage through routine active management of the third stage of labor
- Treatment of postpartum hemorrhage due to uterine atony after delivery of the placenta
- Management of incomplete or inevitable abortion in the second trimester
Non-obstetric indication:
- Facilitation of milk letdown in lactating women (intranasal formulation, less commonly used)
Oxytocin is the first-line uterotonic agent for both prevention and treatment of postpartum hemorrhage. It is included on the WHO Model List of Essential Medicines.
Pharmacokinetics
Route of administration: Intravenous (most common) or intramuscular. Oxytocin is a peptide and is not orally bioavailable due to degradation in the gastrointestinal tract.
Onset of action:
- IV: Uterine contractions begin within 3-5 minutes
- IM: Onset within 3-7 minutes
Duration of action:
- IV infusion: Effects cease within 1 hour after discontinuation
- IM: Contractions may persist for 2-3 hours
Distribution: Small volume of distribution. Does not cross the blood-brain barrier in significant amounts. Minimal placental transfer.
Metabolism: Rapidly metabolized by oxytocinase (placental aminopeptidase) in the liver, kidneys, and plasma. During pregnancy, the placenta produces large amounts of oxytocinase, contributing to rapid clearance.
Elimination: Metabolites excreted in urine. Plasma half-life is approximately 3-10 minutes, which allows for rapid titration during labor.
The short half-life of oxytocin requires continuous IV infusion for sustained uterine activity during labor induction or augmentation.
Adverse effects
Maternal adverse effects:
- Uterine tachysystole (excessive frequency of contractions, >5 in 10 minutes) or hypertonus, which can compromise uteroplacental blood flow
- Uterine rupture (rare but serious, increased risk with prior uterine surgery or high-dose oxytocin)
- Water intoxication and hyponatremia with prolonged high-dose infusion, due to antidiuretic effect; can lead to seizures, coma, or death
- Hypotension (especially with rapid IV bolus)
- Reflex tachycardia
- Nausea and vomiting
- Postpartum hemorrhage paradoxically, if oxytocin receptors become desensitized after prolonged exposure (uterine atony)
Fetal adverse effects:
- Fetal distress secondary to uterine hyperstimulation and reduced placental perfusion
- Neonatal jaundice (increased risk with oxytocin use)
- Fetal bradycardia from umbilical cord compression during strong contractions
Cardiovascular effects:
- Rapid IV administration can cause hypotension, tachycardia, and rarely cardiac arrhythmias or myocardial ischemia
Rare but serious:
- Anaphylaxis (very rare)
- Disseminated intravascular coagulation (DIC)
- Subarachnoid hemorrhage (case reports)
Continuous fetal heart rate monitoring is mandatory during oxytocin administration to detect signs of fetal compromise.
Contraindications and warnings
Absolute contraindications:
- Significant cephalopelvic disproportion
- Unfavorable fetal positions or presentations that are undeliverable without conversion (transverse lie, cord presentation)
- Fetal distress when delivery is not imminent
- Obstetric emergencies requiring surgical intervention (cord prolapse, uterine rupture)
- Prior classical cesarean section or major uterine surgery involving the myometrium
- Active genital herpes infection (vaginal delivery contraindicated)
- Placenta or vasa previa
- Invasive cervical carcinoma
Relative contraindications and warnings:
- Uterine overdistension (polyhydramnios, multiple gestation, fetal macrosomia) increases rupture risk
- Grand multiparity (≥5 prior deliveries) increases sensitivity to oxytocin
- Borderline cephalopelvic disproportion
- Prior low-transverse cesarean section: oxytocin may be used cautiously for trial of labor after cesarean (TOLAC)
- Cardiovascular disease: use caution due to hemodynamic effects
- Hypertonic or hyperactive uterine contractions
Pregnancy category: Not applicable for categorization (used during labor and delivery). Oxytocin is a naturally occurring hormone.
Breastfeeding: Compatible. Oxytocin facilitates milk ejection and does not harm the nursing infant.
Black box warning: Oxytocin carries an FDA boxed warning stating it is not indicated for elective induction of labor. The warning emphasizes that oxytocin should only be used for medically indicated induction or augmentation due to inadequate data on benefits versus risks when used electively. Oxytocin also carries significant risk of uterine hyperstimulation, fetal compromise, and maternal water intoxication. Close monitoring is essential.
Drug interactions
Prostaglandins (misoprostol, dinoprostone):
Concurrent or sequential use with prostaglandins enhances uterine contractility and increases the risk of uterine hyperstimulation and rupture. A waiting period (typically 6-12 hours after prostaglandin administration) is recommended before starting oxytocin.
Other uterotonic agents (methylergonovine, carboprost):
Additive uterotonic effects. These agents may be used in sequence for postpartum hemorrhage management but require careful monitoring for excessive uterine contraction.
Vasoconstrictors and sympathomimetics:
Concurrent use with vasopressors (ephedrine, phenylephrine) may potentiate hypertension. Use caution in women receiving regional anesthesia who may require vasopressor support.
Cyclopropane or halothane anesthesia:
These volatile anesthetics relax uterine smooth muscle and may antagonize oxytocin's effects. They also increase the risk of hypotension and arrhythmias when combined with oxytocin.
Nitric oxide donors and tocolytics:
Agents that relax the uterus (nitroglycerin, magnesium sulfate, terbutaline) may reduce oxytocin effectiveness.
Fluid overload risk:
Oxytocin should be diluted in isotonic saline, not in excessive volumes of hypotonic solutions, to minimize the risk of water intoxication. Avoid concurrent administration of large volumes of electrolyte-free solutions.
No significant interactions with most systemic medications. Oxytocin does not inhibit or induce cytochrome P450 enzymes.
Clinical pearls
Titration is key: Oxytocin must be titrated carefully to achieve adequate uterine contractions (3-5 contractions in 10 minutes) without hyperstimulation. The goal is progressive cervical dilation, not maximal uterine activity.
Continuous monitoring: Continuous electronic fetal heart rate and uterine contraction monitoring is mandatory during oxytocin infusion to detect fetal distress or uterine tachysystole.
Bishop score: The success of labor induction with oxytocin depends on cervical favorability. A Bishop score ≥6 predicts higher success rates. Cervical ripening with prostaglandins may be needed if the cervix is unfavorable.
Uterine atony paradox: Prolonged oxytocin exposure during labor can cause downregulation and desensitization of oxytocin receptors, leading to uterine atony and postpartum hemorrhage. This is managed by discontinuing the infusion and using alternative uterotonics (methylergonovine, carboprost).
Bolus vs. infusion: Oxytocin should never be given as a rapid IV bolus due to the risk of severe hypotension, tachycardia, and cardiac complications. It is administered as a slow infusion or, in emergencies, as a slow IV push over at least 1 minute.
Active management of third stage: Low-dose oxytocin administration immediately after delivery of the anterior shoulder or after placental delivery reduces postpartum hemorrhage risk by 40%.
Water intoxication risk factors: Prolonged infusion (>24 hours), high doses, and dilution in large volumes of electrolyte-free solutions increase the risk of hyponatremia. Monitor fluid balance and electrolytes in prolonged inductions.
Misoprostol vs. oxytocin: In resource-limited settings, oral or sublingual misoprostol is an alternative for labor induction or postpartum hemorrhage prevention, but oxytocin remains the gold standard where available.
Failed induction: If oxytocin fails to achieve adequate cervical change after 12-18 hours of adequate contractions, cesarean delivery is typically recommended.
Practice questions
1. A 28-year-old woman at 41 weeks' gestation is admitted for labor induction. She has an unfavorable cervix (Bishop score 3). Oxytocin infusion is started, and after 8 hours she develops 6-7 contractions every 10 minutes with minimal cervical change. Fetal heart rate shows recurrent late decelerations. What is the most appropriate next step?
2. A 32-year-old woman delivers a healthy infant after a 16-hour oxytocin-augmented labor. Immediately after placental delivery, she develops heavy vaginal bleeding. Her uterus is soft and boggy on palpation. Fundal massage is performed and oxytocin infusion is continued, but bleeding persists. What is the most likely cause of her postpartum hemorrhage?
3. A 35-year-old multiparous woman is receiving oxytocin infusion for labor augmentation. After 20 hours of infusion, she develops confusion and a generalized tonic-clonic seizure. Laboratory studies show serum sodium of 118 mEq/L. Which property of oxytocin is responsible for this complication?
Frequently asked questions
How does oxytocin work?
Oxytocin works by binding to oxytocin receptors on uterine smooth muscle cells, which are Gq protein-coupled receptors. This binding activates phospholipase C, leading to increased intracellular calcium concentration. The elevated calcium triggers actin-myosin interaction, causing rhythmic uterine contractions. Oxytocin also stimulates prostaglandin release from the decidua, further enhancing contractility.
What are the side effects of oxytocin?
The main maternal side effects of oxytocin include uterine tachysystole (excessive contractions), uterine hypertonus, water intoxication with hyponatremia (from prolonged high-dose use), hypotension (especially with rapid bolus), nausea, and rarely uterine rupture. Fetal side effects include fetal distress and bradycardia due to reduced placental perfusion from uterine hyperstimulation. Continuous fetal monitoring is required during oxytocin administration.
When is oxytocin contraindicated?
Oxytocin is contraindicated in situations where vaginal delivery is unsafe or impossible, including significant cephalopelvic disproportion, fetal distress when delivery is not imminent, unfavorable fetal positions that cannot be corrected, prior classical cesarean section or major uterine surgery, placenta or vasa previa, and active genital herpes. It should also be avoided when there is uterine hyperactivity or obstetric emergencies requiring immediate surgical intervention.
What is the difference between oxytocin and misoprostol?
Oxytocin is a peptide hormone given intravenously or intramuscularly for labor induction and postpartum hemorrhage, with a rapid onset (3-5 minutes) and short half-life requiring continuous infusion. Misoprostol is a prostaglandin E1 analogue given orally, sublingually, or vaginally for cervical ripening and labor induction, with slower onset but longer duration of action. Oxytocin is preferred where IV access is available; misoprostol is useful in resource-limited settings but carries higher risk of uterine hyperstimulation.
Can oxytocin cause uterine rupture?
Yes, oxytocin can cause uterine rupture, though it is rare. The risk is highest in women with prior uterine surgery (especially classical cesarean section), grand multiparity, uterine overdistension, or cephalopelvic disproportion. Uterine hyperstimulation from excessive oxytocin dosing increases rupture risk by causing excessive intrauterine pressure. This is why continuous monitoring and careful dose titration are essential, and why oxytocin is contraindicated in high-risk uterine scar situations.
Conditions it is used for
Related drugs
Sources and further reading
DailyMed (FDA labels)StatPearls (NCBI Bookshelf)MedlinePlusWHO ATC/DDD index: H01BB02
Educational content for medical students, prepared by the WhiteCoat Pro editorial team with AI assistance; every page is reviewed by a second AI model for factual errors. It is not medical advice and does not replace the product label, local guidelines or a clinician.